Interestingly, we observed an increase in tumor clearance compared to the lower doses tested earlier, which could be due to a combination of induction of effective T cell responses and CD40-induced Th1 remodeling in lymph nodes and tumor compartments. The gene discussed is CD40; the disease is neoplasm.